Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Adipotide regulatory status

Current status of Adipotide in the United States: Unscheduled. In sport: WADA prohibited. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

What is the current status of Adipotide?

Regulatory: UnscheduledWADA: WADA prohibitedVerified: Verified Sep 29, 2026
FDA and compounding
Not FDA approved and not on any FDA 503A category list (Category 1, 2, 3 or the withdrawn list) or on the 503A bulks list as of the last verification date. Because it is not in Category 1, FDA's interim enforcement policy does not cover it. No USP monograph or approved drug containing it has been identified, so no compounding pharmacy has an identified lawful basis to dispense it. FDA does not publicly categorize nominations made after January 7, 2025, so whether anyone has nominated it is unconfirmed.
WADA
WADA prohibited
Access path
  1. No lawful United States access path identified on the last verified date outside a registered clinical trial. Clinical development stopped after phase 1.
  2. Not available as an FDA approved product and not eligible for compounding under section 503A or 503B.
  3. Products labeled research use only are unapproved drugs when sold for human use and are not verified for identity or purity.

Full Adipotide page: evidence, dosing in the literature, and sources

How has the status of Adipotide changed over time?

No dated regulatory event has been recorded for Adipotide. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for Adipotide and the source of each dated event.

  1. [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA, 2026
  2. [2]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list, content current as of April 22, 2026)FDA, 2026
  3. [3]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
  4. [4]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026